Preclinical Imaging Shared Facility

临床前成像共享设施

• 批准号: 10362787
• 负责人: Anna C. Sorace
• 金额: $ 16.51万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-03-28 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10362787
• 关键词: Animal Model; Animals; Basic Science; Bioluminescence; Blood Vessels; Cancer Detection; Cancer Model; Clinical Trials; Comprehensive Cancer Center; Consultations; Evaluation; Faculty; Fluorescence; Frequencies; Funding; Gamma Cameras; Gamma Rays; Goals; Grant; Human; Image; Image Analysis; Magnetic Resonance Imaging; Malignant Neoplasms; Mass Spectrum Analysis; Measurement; Mission; Molecular; Multimodal Imaging; Pathway interactions; Patients; Positioning Attribute; Positron-Emission Tomography; Pre-Clinical Model; Research; Research Personnel; Resource Sharing; Structure; Technology; Therapy Evaluation; Tissue Procurements; Tissue Sample; Training; Transgenic Animals; Translating; Translations; Ultrasonography; animal imaging; cancer therapy; clinically relevant; cost effective; equipment acquisition; high resolution imaging; human imaging; imaging approach; imaging modality; imaging study; instrument; member; metabolic imaging; microCT; microPET; microPET/CT; microSPECT; molecular imaging; novel imaging technology; novel therapeutics; optical imaging; pre-clinical; pre-clinical research; preclinical imaging; preclinical study; programs; real-time images; receptor; research study; response; single photon emission computed tomography; technology development; translation to humans; tumor

IMAGING GROUP PRECLINICAL IMAGING SHARED FACILITY (PCISF) ABSTRACT The Preclinical Imaging Shared Facility (PCISF) fulfills a critical UAB-CCC priority by supporting over 50 members in five programs with preclinical imaging studies for detection of cancer and therapy evaluation. The facility provides detailed imaging evaluation of new cancer treatments, and thereby accelerates their translation to human trials. The specific aims are the following: (1) to provide state-of-the-art molecular imaging for preclinical studies in appropriate animal models, and support IND's for transition to human imaging studies; (2) to provide consultation and training to CCC members for molecular imaging in cancer models; (3) to establish methods for image analyses; (4) to maintain the instruments and keep them accurately calibrated; and (5) to develop novel imaging technologies and acquire new instruments. The facility will coordinate existing support mechanisms for imaging at UAB, and significantly expand the imaging effort with clinically relevant imaging that can be translated to humans. Imaging components include structural and metabolic imaging (MRI/MRS, high frequency ultrasonography and microCT), gamma-ray imaging (gamma camera, microSPECT/CT, microPET/CT, PET/MR), and optical imaging (bioluminescence and fluorescence). The PCISF has undertaken a multimodality imaging approach to provide a molecular understanding of cancer in animal models by integrating measurements of tumor mass (bioluminescence, ultrasound, CT, and MR), tumor specific targeting (SPECT, ultrasound, fluorescence, microPET), vascular parameters (ultrasound, MR), and specific therapy responses (ultrasound, bioluminescence, SPECT, MR, micoPET). Each imaging modality has advantages and their coordinated application is synergistic. The facility meets a critical need in evaluation of new therapies for cancer in animal models, thereby enabling translation of the new therapies to human trials. The facility will enhance the potential of other UAB-CCC shared facilities (High Resolution Imaging, Tissue Procurement, Mass Spectrometry/Proteonomics, Transgenic Animal, and Human Imaging) by providing real-time imaging of molecular pathways in the living animal, enabling precise tissue sampling and microanalyses, and facilitating translation to human studies.

影像集团 临床前成像共享设施 (PCISF) 抽象的 临床前成像共享设施 (PCISF) 通过支持 50 多个项目满足了 UAB-CCC 的关键优先事项 五个用于癌症检测和治疗评估的临床前成像研究项目的成员。这 设施提供新癌症治疗的详细成像评估，从而加速其转化 到人体试验。具体目标如下：（1）提供最先进的分子成像 在适当的动物模型中进行临床前研究，并支持 IND 过渡到人体成像研究； (2) 为 CCC 成员提供癌症模型分子成像方面的咨询和培训； (3) 建立 图像分析方法； （四）维护仪器仪表并保持准确校准； (5) 至 开发新颖的成像技术并获取新仪器。该设施将协调现有支持 UAB 的成像机制，并通过临床相关成像显着扩展成像工作 可以翻译给人类。成像组件包括结构和代谢成像（MRI/MRS、 高频超声检查和 microCT）、伽马射线成像（伽马相机、microSPECT/CT、 microPET/CT、PET/MR）和光学成像（生物发光和荧光）。 PCISF 已采取 一种多模态成像方法，通过以下方式提供对动物模型中癌症的分子理解 整合肿瘤质量测量（生物发光、超声、CT 和 MR）、肿瘤特异性靶向 （SPECT、超声、荧光、microPET）、血管参数（超声、MR）和特定治疗 反应（超声、生物发光、SPECT、MR、micoPET）。每种成像方式都有优点和 它们的协调应用具有协同作用。该设施满足了评估新疗法的关键需求 动物模型中的癌症，从而使新疗法能够转化为人体试验。该设施将 增强其他 UAB-CCC 共享设施的潜力（高分辨率成像、组织采购、 质谱/蛋白质组学、转基因动物和人类成像）通过提供实时成像 活体动物中的分子途径，实现精确的组织采样和微量分析，并促进 翻译为人类研究。